conivaptan
DrugIV
Other names: Vaprisol, YM087
NCT Number: NCT00379847
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Afula, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IV
Other names: Vaprisol, YM087
Time frame: 96 Hours
Time frame: 96 Hours
Cumberland Pharmaceuticals
Industry
A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00201994
Brain Diseases, Cardiovascular Diseases
Gustav Carus, Dresden, Germany
View Trial DetailsNCT06781710
Demyelinating Diseases, Hyponatremia
Cologne, Germany
View Trial DetailsNCT01212211
Hyponatremia, Metabolic Diseases
Carentan, France
View Trial DetailsNCT07255833
Arrhythmias, Cardiac, Cardiovascular Diseases
Cologne, Germany
View Trial Details